Last updated: September 13, 2026
Leader Allergy Relief D-24 is a private-label extended-release combination product containing loratadine 10 mg and pseudoephedrine sulfate 240 mg per 24-hour tablet. Its commercial position is based on OTC substitution for Claritin-D 24 Hour, with value concentrated in reliable 24-hour release, low-cost excipient sourcing, controlled pseudoephedrine distribution and compliant packaging.
The product has limited conventional patent protection. The main barriers are formulation performance, manufacturing validation, regulatory compliance and access to pseudoephedrine distribution channels.
What is Leader Allergy Relief D-24?
Leader Allergy Relief D-24 is an OTC antihistamine-decongestant product used for temporary relief of allergy symptoms, including nasal congestion, sneezing, runny nose and itchy or watery eyes.
| Attribute |
Product profile |
| Brand |
Leader Allergy Relief D-24 |
| Active ingredients |
Loratadine 10 mg and pseudoephedrine sulfate 240 mg |
| Dosage form |
Extended-release tablet |
| Dosing |
One tablet every 24 hours |
| Antihistamine |
Loratadine |
| Decongestant |
Pseudoephedrine sulfate |
| Regulatory category |
OTC combination drug |
| Primary reference product |
Claritin-D 24 Hour |
| Principal commercial barrier |
Pseudoephedrine control and 24-hour release performance |
The active ingredient combination addresses two different mechanisms. Loratadine blocks peripheral histamine H1 receptors. Pseudoephedrine reduces nasal congestion through vasoconstriction. The formulation must deliver rapid symptom relief while maintaining pseudoephedrine exposure over approximately 24 hours.
What excipients are strategically important in Leader Allergy Relief D-24?
The commercially important excipient system is the extended-release matrix or coating architecture that controls pseudoephedrine release without impairing loratadine dissolution.
Typical excipient functions include:
| Excipient function |
Likely materials |
Commercial purpose |
| Dilution and tablet mass |
Microcrystalline cellulose, lactose or other direct-compression fillers |
Provides compressibility and consistent tablet weight |
| Binder |
Povidone or hydroxypropyl cellulose |
Improves granule and tablet strength |
| Disintegrant |
Croscarmellose sodium or sodium starch glycolate |
Supports immediate or controlled breakup of the tablet structure |
| Lubricant |
Magnesium stearate |
Prevents sticking during compression |
| Glidant |
Colloidal silicon dioxide |
Improves powder flow |
| Release control |
Hydrophilic polymer, coated granules or insoluble polymer system |
Controls pseudoephedrine release |
| Film coating |
Hypromellose, polyethylene glycol, titanium dioxide or colorants |
Protects the tablet and supports identification |
| Moisture control |
Film-coating system and suitable packaging |
Limits degradation and dissolution drift |
The exact Leader formulation should be distinguished from the general generic architecture. A label can identify inactive ingredients, but it does not disclose manufacturing parameters such as granulation endpoint, polymer loading, coating weight gain, compression force or dissolution-control strategy.
Which excipient choices matter most?
The highest-value excipient decisions are:
- The release-controlling polymer system.
- The selection of filler and binder for uniform tablet compression.
- The lubricant level, because excess magnesium stearate can slow dissolution.
- The coating system, especially where pseudoephedrine is incorporated into coated particles.
- Moisture protection during storage and distribution.
A hydrophilic matrix is generally cost-efficient but can create release variability when tablet hardness, polymer hydration or lubricant concentration changes. A multiparticulate or coated-particle system offers tighter release control but increases processing cost and scale-up complexity.
How should the excipient strategy be optimized?
A competitive formulation strategy should preserve the reference product’s dissolution profile while reducing supply-chain cost and manufacturing sensitivity.
Immediate-release loratadine layer
Loratadine is present at a relatively low dose. It requires uniform distribution throughout the tablet, particularly if the product uses direct compression. Content-uniformity risk increases when the active ingredient has poor flow or when the formulation has a large excipient-to-drug ratio.
Useful controls include:
- A pre-blend or ordered mixing process.
- Low-shear blending after lubricant addition.
- Particle-size matching between loratadine and the principal filler.
- In-process blend-uniformity testing.
- Control of segregation during tablet transfer and packaging.
Loratadine also has low aqueous solubility. A formulation that releases loratadine too slowly can create a dissolution or bioequivalence problem even if pseudoephedrine release is acceptable.
Extended-release pseudoephedrine layer
Pseudoephedrine sulfate is present at a high dose and drives tablet size, hardness and release behavior. The formulator must prevent dose dumping while preserving acceptable onset of decongestant activity.
A practical development program should compare:
- Hydrophilic matrix tablets.
- Coated pseudoephedrine granules.
- Insoluble polymer coatings.
- Combination matrix and coating systems.
- Direct compression against wet or dry granulation.
The key analytical endpoint is not a single dissolution time point. The product should match the reference across multiple media and sampling intervals, including early, middle and late release periods.
What FDA regulatory status applies to Leader Allergy Relief D-24?
Leader Allergy Relief D-24 is regulated as an OTC combination product containing an antihistamine and an oral nasal decongestant. Loratadine and pseudoephedrine are established OTC active ingredients, subject to FDA monograph conditions and product-specific requirements where applicable [1][2].
Pseudoephedrine creates additional distribution and consumer-purchase controls. Federal law requires retail controls for products containing pseudoephedrine, including sales-record requirements, purchase limits and restrictions on direct shelf access in many retail environments [3].
The product’s regulatory value is therefore different from that of a standard loratadine tablet. A manufacturer must manage:
- OTC labeling and Drug Facts compliance.
- Pseudoephedrine retail controls.
- State-level sales requirements.
- Child-resistant or tamper-related packaging considerations where applicable.
- Stability of the extended-release dosage form.
- Dissolution and assay control.
- Manufacturing records supporting release consistency.
What patents protect Leader Allergy Relief D-24?
The original composition and use patents associated with loratadine and loratadine-pseudoephedrine products are generally expired or commercially weak in the United States. The primary Claritin and Claritin-D patent estates were developed decades ago, and the active ingredients are now widely available in generic and store-brand products.
| Protection category |
Current commercial significance |
| Loratadine compound patents |
Generally expired |
| Pseudoephedrine compound patents |
Expired or not commercially relevant |
| Original combination patents |
Generally expired or limited |
| Extended-release formulation patents |
Potentially relevant only if claims remain enforceable and cover the marketed design |
| Manufacturing patents |
Relevant if they claim a difficult release-control process |
| Packaging patents |
Usually narrow and easy to design around |
| Trademark rights |
Leader and Claritin branding remain distinct |
Leader Allergy Relief D-24 is not protected merely because it uses an extended-release tablet. Patent strength depends on whether a live claim covers the specific polymer system, coated-particle structure, release profile or manufacturing process.
Is Leader Allergy Relief D-24 listed in the Orange Book?
The Orange Book is principally relevant to approved prescription and certain nonprescription drug applications. OTC products marketed under the FDA monograph system generally do not obtain the same Orange Book exclusivity position as prescription NDA products [4].
For a private-label OTC product, commercial protection usually comes from:
- Brand ownership.
- Retailer contracts.
- Manufacturer qualification.
- Label and packaging rights.
- Supply agreements.
- Product-specific quality data.
- Distribution access for pseudoephedrine.
Orange Book listings associated with historical loratadine-pseudoephedrine NDA products may provide background on the reference-product history, but they do not create a meaningful exclusivity period for a compliant private-label OTC product.
When does Leader Allergy Relief D-24 lose exclusivity?
Leader Allergy Relief D-24 has no meaningful market exclusivity tied to the loratadine-pseudoephedrine active ingredient combination. Generic and store-brand competition can enter through the OTC monograph pathway, subject to FDA requirements.
The principal commercial exclusivity is retailer-based rather than patent-based. A competing manufacturer can enter if it can:
- Manufacture a compliant 24-hour tablet.
- Match the relevant performance specifications.
- Obtain retail distribution.
- Comply with pseudoephedrine controls.
- Offer a price that supports retailer margin.
- Maintain uninterrupted active-ingredient and excipient supply.
There is no conventional Paragraph IV exposure for a monograph-compliant private-label product unless the product is marketed under an approved application that implicates listed patents.
What generic launch risks exist?
Generic launch risk is high at the molecule level and moderate at the finished-product level.
High-risk areas
- Price competition from national retailers.
- Substitution by loratadine-only products when congestion is not the primary symptom.
- Consumer migration to cetirizine or fexofenadine products.
- Pseudoephedrine purchase restrictions.
- Retailer concerns about inventory controls and theft.
- Supply shortages involving pseudoephedrine sulfate.
- Dissolution drift after excipient or supplier changes.
Lower-risk areas
- Active-ingredient patent litigation.
- Biosimilar competition.
- Conventional Paragraph IV litigation.
- New chemical entity exclusivity.
- API differentiation.
Biosimilar risk is not applicable. Leader Allergy Relief D-24 is a small-molecule OTC product, not a biologic.
What commercial opportunities exist for excipient suppliers?
Excipient suppliers can create value in four areas.
1. Lower-cost release-control systems
A polymer system that reproduces the reference dissolution profile with fewer processing steps can reduce cost per tablet. The strongest opportunity is a directly compressible or dry-granulated release-control excipient that reduces dependence on specialized coating equipment.
2. Robustness against manufacturing variation
Suppliers can differentiate through excipients that tolerate changes in compression force, humidity and lubricant concentration. Robustness reduces batch failures and post-approval change risk.
3. Moisture and stability management
A low-moisture excipient platform, high-barrier blister or bottle system can protect dissolution performance during long retail storage. Packaging and excipient design should be evaluated together because moisture uptake can change polymer hydration and release rate.
4. Private-label platform development
A validated platform for loratadine-pseudoephedrine 24-hour tablets can support multiple retailer brands. The commercial model is attractive because the same formulation and manufacturing process can serve several labels with limited artwork and packaging changes.
How does Leader Allergy Relief D-24 compare with competing allergy products?
| Product category |
Active ingredients |
Congestion relief |
24-hour dosing |
Excipient opportunity |
| Leader Allergy Relief D-24 |
Loratadine/pseudoephedrine |
Yes |
Yes |
Release-control and cost reduction |
| Loratadine 24-hour tablet |
Loratadine |
No or limited |
Yes |
Low-cost immediate-release platform |
| Cetirizine 24-hour tablet |
Cetirizine |
No |
Yes |
High-volume conventional tablet |
| Fexofenadine 24-hour tablet |
Fexofenadine |
No |
Yes |
Larger tablet and dissolution optimization |
| Loratadine-pseudoephedrine 12-hour tablet |
Loratadine/pseudoephedrine |
Yes |
No |
Smaller dose, twice-daily positioning |
| Nasal decongestant products |
Varies |
Yes |
Varies |
Spray and preservative systems |
The D-24 product occupies a higher-complexity position than a standard antihistamine tablet because it combines a low-dose antihistamine with a high-dose controlled-release decongestant.
What manufacturing and IP barriers affect the product?
The strongest manufacturing barrier is reproducible pseudoephedrine release at commercial scale. A formulation can pass laboratory development and still fail after scale-up because of altered granule density, coating uniformity, tablet hardness or equipment residence time.
Relevant IP opportunities include:
- Polymer composition claims.
- Coated-particle claims.
- Multiparticulate tablet claims.
- Process-control claims.
- Moisture-resistant packaging claims.
- Abuse-deterrent or tamper-resistant pseudoephedrine systems.
These claims must be narrow enough to survive examination and broad enough to cover commercial manufacturing. Broad claims directed only to loratadine, pseudoephedrine or their combination are unlikely to provide meaningful current protection.
What is the commercial outlook for Leader Allergy Relief D-24?
The product is best viewed as a stable private-label OTC platform rather than a patent-protected asset. Revenue depends on retail distribution, private-label pricing, consumer recognition and continuous supply.
The most attractive opportunities are:
- Retailer-exclusive versions.
- Club-store multipacks.
- E-commerce packs with compliant pseudoephedrine controls.
- Lower-cost formulations using validated excipient substitutions.
- Improved moisture protection.
- Child-resistant and senior-friendly packaging variants.
- Contract manufacturing for multiple store brands.
- Geographic expansion where pseudoephedrine OTC rules permit sale.
Revenue exposure is concentrated in retail volume and margin, not licensing royalties. A manufacturer with a validated formulation, reliable pseudoephedrine sourcing and strong retailer relationships can compete despite the absence of meaningful active-ingredient exclusivity.
Key Takeaways
- Leader Allergy Relief D-24 is a loratadine 10 mg/pseudoephedrine sulfate 240 mg extended-release OTC tablet.
- The commercial formulation challenge is controlling pseudoephedrine release while maintaining loratadine dissolution and content uniformity.
- The most valuable excipient opportunities involve release-control polymers, direct compression, moisture protection and formulation robustness.
- Active-ingredient patents do not provide meaningful current exclusivity.
- Paragraph IV and biosimilar risks are limited or inapplicable for this private-label OTC product.
- Pseudoephedrine distribution controls, retailer access and manufacturing consistency are the principal commercial barriers.
- A validated excipient and manufacturing platform can support multiple private-label products.
FAQs About Leader Allergy Relief D-24
Is Leader Allergy Relief D-24 the same as Claritin-D 24 Hour?
It is positioned as a private-label equivalent containing the same active-ingredient combination and 24-hour dosing concept. Inactive ingredients, manufacturing processes, tablet design and packaging may differ.
Can a manufacturer replace the excipients in Leader Allergy Relief D-24?
Yes, but the manufacturer must demonstrate that the change does not alter assay, content uniformity, stability, tablet performance or dissolution. Release-controlling excipient changes carry the highest technical risk.
Does Leader Allergy Relief D-24 have biosimilar competition?
No. It is a small-molecule OTC drug, so biosimilar pathways do not apply.
Are pseudoephedrine products subject to special retail controls?
Yes. Federal and state requirements can impose purchase limits, identification procedures, sales records and behind-the-counter distribution controls [3].
Is the product a strong patent-licensing opportunity?
Usually not on the basis of the active ingredients. The stronger licensing opportunities involve a differentiated extended-release platform, validated manufacturing process, moisture-control system or retailer-specific product platform.
References
-
U.S. Food and Drug Administration. (2023). Over-the-counter monograph M012: Cold, cough, allergy, bronchodilator, and anti-asthmatic drug products. FDA.
-
U.S. Food and Drug Administration. (2023). 21 C.F.R. Part 341: Cold, cough, allergy, bronchodilator, and anti-asthmatic drug products for over-the-counter human use. Electronic Code of Federal Regulations.
-
U.S. Drug Enforcement Administration. (2024). Combat Methamphetamine Epidemic Act and retail pseudoephedrine requirements. U.S. Department of Justice.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
